摘要
慢性髓性白血病(CML)属于多能造血干细胞恶性骨髓增生性疾病,费城(Ph)染色体是CML的细胞遗传学标志,90%以上CML患者骨髓细胞中发现有Ph染色体。经过20年的研究,CML患者的生存预后得到显著改善,特别是伊马替尼(imatinib,商品名格列卫)成功应用于临床治疗CML。伊马替尼是酪氨酸激酶抑制剂,目前是CML慢性期(CML-CP)最有效的靶向治疗药物。2009年ASH年会上报告了伊马替尼用于CML一线治疗的IRIS研究(国际干扰素和STI571随机研究)随访8年的最新结果,本文对该项研究结果进行综述。
Chronic myelogeous leukemia（CML） is a myeloproliferative disorder of pluripotent hematopoietic stem cells,of which cell genetic marker is Philadelphia（Ph） chromosome,and above 90 percent of patients with CML have this chromosome in their myeloid cells.In the past 20 years,the life quality and the overall survival of CML patients have been improved greatly,especially the significant achievement from imatinib（Glivec）.Imatinib is a tyrosine kinase inhibitor and so far it is the most effective target therapy drug for the CML-CP.The latest results of 8-year follow-up of IRIS（International Randomized Study of Interferon vs STI571） study have been reported at the 2009 ASH annual meeting.This paper reviews the study results.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第17期1556-1557,1562,共3页
Chinese Journal of New Drugs
